Baseline characteristics in the overall population (N = 90) and cohorts of patients with (n = 49) or without (n = 41) a CR at EOT
| . | Patients with CR at EOT (n = 49) . | Patients without CR at EOT (n = 41) . | All patients (N = 90) . |
|---|---|---|---|
| Median age (range), y | 63 (29-90) | 59 (35-83) | 60 (29-90) |
| Age 18-65 y, n (%) | 30 (61.2) | 32 (78.0) | 62 (68.9) |
| Age >65 y, n (%) | 19 (38.8) | 9 (22.0) | 28 (31.1) |
| Male, n (%) | 26 (53.1) | 29 (70.7) | 55 (61.1) |
| ECOG PS at baseline, n (%) | |||
| 0 | 30 (61.2) | 23 (56.1) | 53 (58.9) |
| 1 | 19 (38.8) | 18 (43.9) | 37 (41.1) |
| Ann Arbor stage, n (%) | |||
| I-II | 9 (18.4) | 12 (29.3) | 21 (23.3) |
| III-IV | 40 (81.6) | 29 (70.7) | 69 (76.7) |
| Bulky disease (>6 cm), n (%) | 15 (30.6) | 16 (39.0) | 31 (34.4) |
| Median no. of prior lines of therapy (range) | 3 (2-10) | 3 (2-7) | 3 (2-10) |
| 2 prior lines, n (%) | 22 (44.9) | 13 (31.7) | 35 (38.9) |
| ≥3 prior lines, n (%) | 27 (55.1) | 28 (68.2) | 55 (61.1) |
| Prior cancer therapies, n (%) | |||
| ASCT | 15 (30.6) | 13 (31.7) | 28 (31.1) |
| Anti-CD20 therapy | 49 (100.0) | 41 (100.0) | 90 (100.0) |
| Alkylator therapy | 49 (100.0) | 41 (100.0) | 90 (100.0) |
| CAR T-cell therapy | 1 (2.0) | 2 (4.9) | 3 (3.3) |
| Anthracyclines | 39 (79.6) | 35 (85.4) | 74 (82.2) |
| PI3K inhibitor | 11 (22.4) | 6 (14.6) | 17 (18.9) |
| BTK inhibitor | 4 (8.2) | 2 (4.9) | 6 (6.7) |
| Immunomodulatory drug | 4 (8.2) | 9 (22.0) | 13 (14.4) |
| Bendamustine | 29 (59.2) | 30 (73.2) | 59 (65.6) |
| Refractory to last prior therapy, n (%) | 27 (55.1) | 35 (85.4) | 62 (68.9) |
| Refractory to prior anti-CD20 therapy, n (%) | 35 (71.4) | 36 (87.8) | 71 (78.9) |
| Double refractory,∗ n (%) | 20 (40.8) | 28 (68.3) | 48 (53.3) |
| POD24, n (%) | 26 (53.1) | 21 (51.2) | 47 (52.2) |
| . | Patients with CR at EOT (n = 49) . | Patients without CR at EOT (n = 41) . | All patients (N = 90) . |
|---|---|---|---|
| Median age (range), y | 63 (29-90) | 59 (35-83) | 60 (29-90) |
| Age 18-65 y, n (%) | 30 (61.2) | 32 (78.0) | 62 (68.9) |
| Age >65 y, n (%) | 19 (38.8) | 9 (22.0) | 28 (31.1) |
| Male, n (%) | 26 (53.1) | 29 (70.7) | 55 (61.1) |
| ECOG PS at baseline, n (%) | |||
| 0 | 30 (61.2) | 23 (56.1) | 53 (58.9) |
| 1 | 19 (38.8) | 18 (43.9) | 37 (41.1) |
| Ann Arbor stage, n (%) | |||
| I-II | 9 (18.4) | 12 (29.3) | 21 (23.3) |
| III-IV | 40 (81.6) | 29 (70.7) | 69 (76.7) |
| Bulky disease (>6 cm), n (%) | 15 (30.6) | 16 (39.0) | 31 (34.4) |
| Median no. of prior lines of therapy (range) | 3 (2-10) | 3 (2-7) | 3 (2-10) |
| 2 prior lines, n (%) | 22 (44.9) | 13 (31.7) | 35 (38.9) |
| ≥3 prior lines, n (%) | 27 (55.1) | 28 (68.2) | 55 (61.1) |
| Prior cancer therapies, n (%) | |||
| ASCT | 15 (30.6) | 13 (31.7) | 28 (31.1) |
| Anti-CD20 therapy | 49 (100.0) | 41 (100.0) | 90 (100.0) |
| Alkylator therapy | 49 (100.0) | 41 (100.0) | 90 (100.0) |
| CAR T-cell therapy | 1 (2.0) | 2 (4.9) | 3 (3.3) |
| Anthracyclines | 39 (79.6) | 35 (85.4) | 74 (82.2) |
| PI3K inhibitor | 11 (22.4) | 6 (14.6) | 17 (18.9) |
| BTK inhibitor | 4 (8.2) | 2 (4.9) | 6 (6.7) |
| Immunomodulatory drug | 4 (8.2) | 9 (22.0) | 13 (14.4) |
| Bendamustine | 29 (59.2) | 30 (73.2) | 59 (65.6) |
| Refractory to last prior therapy, n (%) | 27 (55.1) | 35 (85.4) | 62 (68.9) |
| Refractory to prior anti-CD20 therapy, n (%) | 35 (71.4) | 36 (87.8) | 71 (78.9) |
| Double refractory,∗ n (%) | 20 (40.8) | 28 (68.3) | 48 (53.3) |
| POD24, n (%) | 26 (53.1) | 21 (51.2) | 47 (52.2) |
ASCT, autologous stem cell transplant; BTK, Bruton’s tyrosine kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; PI3K, phosphoinositide 3-kinase.
Double refractory to prior anti-CD20 and alkylator therapy.